Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5621
- Registration Number
- NCT06627335
- Locations
- 🇺🇸
Syneos Health (remote site), Morrisville, North Carolina, United States
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 572
- Registration Number
- NCT06615050
- Locations
- 🇺🇸
University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT06585774
- Locations
- 🇺🇸
Texas Transplant Institute, San Antonio, Texas, United States
🇫🇷Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse, France
🇩🇪University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 168
- Registration Number
- NCT06555081
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
- Conditions
- NonSegmental Vitiligo
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 180
- Registration Number
- NCT06548360
- Locations
- 🇺🇸
Skin Care Research, Llc, Hollywood, Florida, United States
🇺🇸Encore Medical Research, Llc Boynton Beach, Boynton Beach, Florida, United States
🇺🇸Pediatric Skin Research Llc, Coral Gables, Florida, United States
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT06516952
- Locations
- 🇵🇱
Diamond Clinic Sp. Z O.O., Krakow, Poland
🇺🇸Cahaba Dermatology, Birmingham, Alabama, United States
🇺🇸Banner - University Medicine Multispecialty Services Clinic, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT06516965
- Locations
- 🇺🇸
Chicago Cosmetic Surgery and Dermatology, Chicago, Illinois, United States
🇺🇸Dermatology Specialists Research Indiana, Clarksville, Indiana, United States
🇺🇸Southern Indiana Clinical Trials, New Albany, Indiana, United States
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT06505265
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06465433
- Locations
- 🇮🇹
Hospital S.M. Terni University of Perugia, Terni, Italy
🇪🇸Clinica Universitad de Navarra, Pamplona, Spain
🇭🇺Petz Aladar County Teaching Hospital, Gyor, Hungary
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT06441318
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States